Ascendiant Capital Maintains Buy on Aemetis, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 89.4%

Neg 0% Neu 0% Pos 89.4%

Ascendiant Capital analyst Edward Woo maintains Aemetis (NASDAQ:AMTX) with a Buy and raises the price target from $20 to $21.